NuVasive price target lowered to $59 from $70 at BTIG

BTIG analyst Ryan Zimmerman lowered his price target on NuVasive to $59 after meeting with its CEO Chris Barry, saying that he was “upfront” about the company FY18 results and may take the opportunity to reset expectations entering FY19. The analyst also keeps his Buy rating on NuVasive shares, noting that its valuation is at a 3-year lows even though the company is looking to accelerate its potential robotic commercialization.
https://thefly.com/landingPageNews.php?id=2850165